| First Author | Gerber DE | Year | 2010 |
| Journal | Cancer Cell | Volume | 18 |
| Issue | 6 | Pages | 548-51 |
| PubMed ID | 21156280 | Mgi Jnum | J:167436 |
| Mgi Id | MGI:4868290 | Doi | 10.1016/j.ccr.2010.11.033 |
| Citation | Gerber DE, et al. (2010) ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18(6):548-51 |
| abstractText | It was only 3 years ago that an acquired translocation of EML4 with ALK leading to the expression of an EML4-ALK oncoprotein in non-small cell lung cancer (NSCLC) was reported. Tumor cells expressing EML4-ALK are 'addicted' to its continued function. Now, crizotinib, an oral ALK inhibitor, is demonstrated to provide dramatic clinical benefit with little toxicity in patients having such advanced NSCLC, and a mechanism of clinical resistance to crizotinib is identified. Such therapy 'targeted' at oncogenic proteins provides 'personalized' medicine and prompts genome-wide mutation analysis of human tumors to find other therapeutic targets. |
